In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary

MeSH terms

• Administration, Oral
• Clinical Trials as Topic
• Glatiramer Acetate
• Humans
• Immunologic Factors / administration & dosage
• Immunologic Factors / adverse effects*
• Immunologic Factors / economics
• Interferons / administration & dosage
• Interferons / adverse effects*
• Interferons / economics
• Multiple Sclerosis / drug therapy*
• Multiple Sclerosis / economics
• Peptides / administration & dosage
• Peptides / adverse effects*